Labcorp Holdings Inc. LH
Labcorp Holdings Inc. (NYSE: LH) is a diagnostics company. Its next catalyst on record is Prenatal Health testing business acquisition: Transaction close (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Prenatal Health testing business acquisition — Transaction close (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Recent results and decisions
- Oct 28, 2026approval FDA approved PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma.
Received FDA approval of PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.